Acuitas Therapeutics and collaborators demonstrate strong protection against P. vivax malaria with mRNA-LNP vaccine
Read about Acuitas Therapeutics and collaborators demonstrate strong protection against P. vivax malaria with mRNA-LNP vaccine
Acuitas Therapeutics announces oral presentations at the 2025 Alliance for mRNA Medicines’ Annual Meeting
Read about Acuitas Therapeutics announces oral presentations at the 2025 Alliance for mRNA Medicines’ Annual Meeting
Acuitas Therapeutics contributes to new insights into broadly neutralizing antibodies induced by COVID-19 mRNA vaccines
Read about Acuitas Therapeutics contributes to new insights into broadly neutralizing antibodies induced by COVID-19 mRNA vaccines
Acuitas Therapeutics’ scientists collaborate with the University of Zurich and the University of Pennsylvania to develop a novel deep learning model for efficient adenine base editing
Read about Acuitas Therapeutics’ scientists collaborate with the University of Zurich and the University of Pennsylvania to develop a novel deep learning model for efficient adenine base editing
Acuitas Therapeutics presents new method for mRNA-LNP production using preformed vesicles at CRS 2025
Read about Acuitas Therapeutics presents new method for mRNA-LNP production using preformed vesicles at CRS 2025
Acuitas Therapeutics and researchers at the University of Pennsylvania demonstrate enhanced T cell immunity with IL-12 mRNA-LNP adjuvant
Read about Acuitas Therapeutics and researchers at the University of Pennsylvania demonstrate enhanced T cell immunity with IL-12 mRNA-LNP adjuvant
Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease
Read about Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease
Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025
Read about Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025
Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development
Read about Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development
Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025
Read about Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025
Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025
Read about Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025
Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024
Read about Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024